join the brightest at bluebird.

join the brightest at bluebird.

With its lentiviral-based gene therapy and gene editing capabilities, bluebird bio has built an integrated product platform with broad potential application to severe genetic diseases and T cell-based immunotherapy. bluebird bio currently has two programs in clinical development – its Lenti-D™ candidate for the treatment of childhood cerebral adrenoleukodystrophy and its LentiGlobin® candidate for the treatment of beta-thalassemia major or severe sickle cell disease. bluebird bio also has a preclinical CAR T cancer immunotherapy program in collaboration with Celgene Corporation, as well as discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies.